Skip Navigation



Annals of Oncology Advance Access published online on October 13, 2009
Annals of Oncology, doi:10.1093/annonc/mdp395
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cervetti, G.
Right arrow Articles by Petrini, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cervetti, G.
Right arrow Articles by Petrini, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)

G. Cervetti*, S. Galimberti, E. Sordi, G. Buda, E. Orciuolo, N. Cecconi and M. Petrini

Section of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, Pisa, Italy

* Correspondence to: Dr G. Cervetti, Section of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, Ospedale S. Chiara, Via Roma 56, 56100 Pisa, Italy. Tel: +39050992815; Fax: +39050830162; E-mail: juliacervetti{at}alice.it

Background: Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is an indolent lymphoma that typically affects elderly patients. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best therapeutic strategy has not yet been identified. Among different possible chemotherapeutic approaches, purine analogues, alone or in association with rituximab, seem to be a valid therapeutic choice.

Patients and methods: Fifty SMZL patients were treated with cladribine with or without anti-CD20 mAb.

Results: Forty-six of 50 patients were assessable for response. Overall response rate was 87%: 24 of 46 patients (52%) achieved a complete hematological response (CR), 16 of 46 (35%) a partial response and 6 (13%) were unresponsive. Interestingly, 15 of 24 cases (62%) in CR also achieved a molecular remission.

Conclusions: The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease.

cladribine, rituximab, splenic marginal zone lymphoma

Received for publication February 22, 2009. Revision received May 20, 2009. Accepted for publication July 8, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.